GW Pharma rolls out Sativex in Denmark
Developed by GW Pharma, Sativex oromucosal spray is indicated as a treatment for the relief of spasticity in multiple sclerosis (MS). The spray is already been marketed in
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.